ICU
ICU's fundamental standing is weak, scoring only 1.1/10. Key concerns include negative Asset-MV (-0.50) and Revenue-MV (-2.11) values, indicating the company holds less assets and generates lower revenue than market-matched peers, historically associated with poor returns. Net income-to-revenue is also negative (-0.17), further highlighting operational inefficiencies. Although Cash-UP (-0.06) and Net profit/Total profit (100%) appear favorable, they are outweighed by other deficits. The ROA (-91.6) and net profit margin on assets (-122.1) are severely negative, confirming subpar asset utilization. Interest coverage (15.48) is decent but insufficient to offset broader weaknesses. Overall, the fundamental picture is deteriorating, leading to an 'Underperform' rating.
Analysis Checks(5/10)
- ICU scores 1.12/10 on fundamentals and holds a Premium valuation at present. Backed by its -199.25% ROE, -1551.08% net margin, -0.69 P/E ratio, 0.82 P/B ratio, and 88.92% earnings growth, these metrics solidify its Underperform investment rating.
